148 related articles for article (PubMed ID: 19011146)
1. Glycemic control in patients with type 2 diabetes mellitus with a disease-specific enteral formula: stage II of a randomized, controlled multicenter trial.
Pohl M; Mayr P; Mertl-Roetzer M; Lauster F; Haslbeck M; Hipper B; Steube D; Tietjen M; Eriksen J; Rahlfs VW
JPEN J Parenter Enteral Nutr; 2009; 33(1):37-49. PubMed ID: 19011146
[TBL] [Abstract][Full Text] [Related]
2. Glycaemic control in type II diabetic tube-fed patients with a new enteral formula low in carbohydrates and high in monounsaturated fatty acids: a randomised controlled trial.
Pohl M; Mayr P; Mertl-Roetzer M; Lauster F; Lerch M; Eriksen J; Haslbeck M; Rahlfs VW
Eur J Clin Nutr; 2005 Nov; 59(11):1221-32. PubMed ID: 16077745
[TBL] [Abstract][Full Text] [Related]
3. Improved Glucose Profile in Patients With Type 2 Diabetes With a New, High-Protein, Diabetes-Specific Tube Feed During 4 Hours of Continuous Feeding.
Lansink M; Hofman Z; Genovese S; Rouws CHFC; Ceriello A
JPEN J Parenter Enteral Nutr; 2017 Aug; 41(6):968-975. PubMed ID: 26826263
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of very low carbohydrate diet in patients with diabetic kidney disease-A randomized controlled trial.
Zainordin NA; Eddy Warman NA; Mohamad AF; Abu Yazid FA; Ismail NH; Chen XW; Koshy M; Abdul Rahman TH; Mohd Ismail N; Abdul Ghani R
PLoS One; 2021; 16(10):e0258507. PubMed ID: 34644368
[TBL] [Abstract][Full Text] [Related]
5. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
6. The Effect of Diabetes-Specific Enteral Nutrition Formula on Cardiometabolic Parameters in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.
Ojo O; Weldon SM; Thompson T; Crockett R; Wang XH
Nutrients; 2019 Aug; 11(8):. PubMed ID: 31443185
[TBL] [Abstract][Full Text] [Related]
7. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.
Yki-Järvinen H; Dressler A; Ziemen M;
Diabetes Care; 2000 Aug; 23(8):1130-6. PubMed ID: 10937510
[TBL] [Abstract][Full Text] [Related]
8. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group.
Riddle MC; Schneider J
Diabetes Care; 1998 Jul; 21(7):1052-7. PubMed ID: 9653594
[TBL] [Abstract][Full Text] [Related]
9. Glycemic Effects of a Low-Carbohydrate Enteral Formula Compared With an Enteral Formula of Standard Composition in Critically Ill Patients: An Open-Label Randomized Controlled Clinical Trial.
van Steen SC; Rijkenberg S; Sechterberger MK; DeVries JH; van der Voort PHJ
JPEN J Parenter Enteral Nutr; 2018 Aug; 42(6):1035-1045. PubMed ID: 30133840
[TBL] [Abstract][Full Text] [Related]
10. Diabetes-specific enteral nutrition formula in hyperglycemic, mechanically ventilated, critically ill patients: a prospective, open-label, blind-randomized, multicenter study.
Mesejo A; Montejo-González JC; Vaquerizo-Alonso C; Lobo-Tamer G; Zabarte-Martinez M; Herrero-Meseguer JI; Acosta-Escribano J; Blesa-Malpica A; Martinez-Lozano F
Crit Care; 2015 Nov; 19():390. PubMed ID: 26549276
[TBL] [Abstract][Full Text] [Related]
11. Slowly digestible carbohydrate sources can be used to attenuate the postprandial glycemic response to the ingestion of diabetes-specific enteral formulas.
Vanschoonbeek K; Lansink M; van Laere KM; Senden JM; Verdijk LB; van Loon LJ
Diabetes Educ; 2009; 35(4):631-40. PubMed ID: 19448045
[TBL] [Abstract][Full Text] [Related]
12. [The effect of enteral nutritional suspension (diabetes) (TPF-DM) on blood glucose, serum insulin and lipids in patients with type 2 diabetes].
Li YX; Pan SH; Zeng JB; Yu K; Sun Q; Liu QY; Qin W; Zhang Q; Pan QR; Yu JC; Xu T; Han SM; Wang H
Zhonghua Nei Ke Za Zhi; 2007 Mar; 46(3):193-6. PubMed ID: 17547798
[TBL] [Abstract][Full Text] [Related]
13. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.
Buse JB; Rubin CJ; Frederich R; Viraswami-Appanna K; Lin KC; Montoro R; Shockey G; Davidson JA
Clin Ther; 2005 Aug; 27(8):1181-95. PubMed ID: 16199244
[TBL] [Abstract][Full Text] [Related]
14. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
Yale JF; Valiquett TR; Ghazzi MN; Owens-Grillo JK; Whitcomb RW; Foyt HL
Ann Intern Med; 2001 May; 134(9 Pt 1):737-45. PubMed ID: 11329231
[TBL] [Abstract][Full Text] [Related]
15. Addition of benfluorex to biguanide improves glycemic control in obese non-insulin-dependent diabetes: a double-blind study versus placebo.
Roger P; Auclair J; Drain P
J Diabetes Complications; 1999; 13(2):62-7. PubMed ID: 10432168
[TBL] [Abstract][Full Text] [Related]
16. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.
Robinson AC; Burke J; Robinson S; Johnston DG; Elkeles RS
Diabetes Care; 1998 May; 21(5):701-5. PubMed ID: 9589227
[TBL] [Abstract][Full Text] [Related]
17. Comparison of a high-protein disease-specific enteral formula with a high-protein enteral formula in hyperglycemic critically ill patients.
Mesejo A; Acosta JA; Ortega C; Vila J; Fernández M; Ferreres J; Sanchis JC; López F
Clin Nutr; 2003 Jun; 22(3):295-305. PubMed ID: 12765670
[TBL] [Abstract][Full Text] [Related]
18. The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials.
Rajagopalan R; Xu Y; Abbadessa M;
Am J Geriatr Pharmacother; 2006 Jun; 4(2):123-33. PubMed ID: 16860259
[TBL] [Abstract][Full Text] [Related]
19. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.
Mattoo V; Eckland D; Widel M; Duran S; Fajardo C; Strand J; Knight D; Grossman L; Oakley D; Tan M;
Clin Ther; 2005 May; 27(5):554-67. PubMed ID: 15978304
[TBL] [Abstract][Full Text] [Related]
20. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.
Tan M; Johns D; González Gálvez G; Antúnez O; Fabián G; Flores-Lozano F; Zúñiga Guajardo S; Garza E; Morales H; Konkoy C; Herz M;
Clin Ther; 2004 May; 26(5):680-93. PubMed ID: 15220012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
